First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase...

Dostarlimab-gxly Market to Expand at a CAGR of 15.6% during 2023-2031, Says Growth Plus Reports Newark, New Castle, USA, May 24, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global dostarlimab-gxly market was conducted by Growth Plus Reports in 2022. The market is expected to hit a...